RARITAN, N.J., Dec. 1 (HSMN NewsFeed) — Johnson & Johnson Clinical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER…
Biopharmaceuticals, FDA
Johnson & Johnson, tapentadol, Ortho-McNeil-Janssen Pharmaceuticals

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain”
Leave a Comment